Which has stronger valuation & earnings, ILMN or QGEN?

Illumina has higher revenue and earnings than Qiagen. Qiagen is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Illumina $4.34B 7.92 $850M $5.36 42.48 Qiagen $2.09B 4.31 $424.88M $1.95 22.41

Is ILMN or QGEN more profitable?

Qiagen has a net margin of 19.49% compared to Illumina's net margin of 18.36%. Illumina's return on equity of 29.84% beat Qiagen's return on equity. Company Net Margins Return on Equity Return on Assets Illumina 18.36% 29.84% 12.17% Qiagen 19.49% 14.47% 8.34%

Does the media prefer ILMN or QGEN?

In the previous week, Illumina had 35 more articles in the media than Qiagen. MarketBeat recorded 53 mentions for Illumina and 18 mentions for Qiagen. Illumina's average media sentiment score of 1.10 beat Qiagen's score of 0.16 indicating that Illumina is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Illumina 38 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to QGEN or MTD?

In the previous week, Mettler-Toledo International had 5 more articles in the media than Qiagen. MarketBeat recorded 23 mentions for Mettler-Toledo International and 18 mentions for Qiagen. Mettler-Toledo International's average media sentiment score of 1.51 beat Qiagen's score of 0.16 indicating that Mettler-Toledo International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mettler-Toledo International 22 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better earnings and valuation, QGEN or MEDP?

Medpace has higher revenue and earnings than Qiagen. Qiagen is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 4.31 $424.88M $1.95 22.41 Medpace $2.53B 6.75 $451.12M $17.06 35.85

Is QGEN or MEDP more profitable?

Qiagen has a net margin of 19.49% compared to Medpace's net margin of 17.67%. Medpace's return on equity of 110.15% beat Qiagen's return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.49% 14.47% 8.34% Medpace 17.67% 110.15% 24.84%

Does the media refer more to QGEN or MEDP?

In the previous week, Medpace had 29 more articles in the media than Qiagen. MarketBeat recorded 47 mentions for Medpace and 18 mentions for Qiagen. Medpace's average media sentiment score of 0.99 beat Qiagen's score of 0.16 indicating that Medpace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Medpace 32 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRL or QGEN?

In the previous week, Charles River Laboratories International and Charles River Laboratories International both had 18 articles in the media. Charles River Laboratories International's average media sentiment score of 0.37 beat Qiagen's score of 0.16 indicating that Charles River Laboratories International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Charles River Laboratories International 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Qiagen 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, QGEN or RVTY?

Qiagen has higher earnings, but lower revenue than Revvity. Qiagen is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 4.31 $424.88M $1.95 22.41 Revvity $2.91B 4.96 $241.20M $2.10 61.57

Is QGEN or RVTY more profitable?

Qiagen has a net margin of 19.49% compared to Revvity's net margin of 8.16%. Qiagen's return on equity of 14.47% beat Revvity's return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.49% 14.47% 8.34% Revvity 8.16% 8.34% 5.01%

Does the media refer more to QGEN or RVTY?

In the previous week, Revvity had 14 more articles in the media than Qiagen. MarketBeat recorded 32 mentions for Revvity and 18 mentions for Qiagen. Revvity's average media sentiment score of 1.06 beat Qiagen's score of 0.16 indicating that Revvity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Revvity 19 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Qiagen (QGEN) Competitors

$43.70 +0.34 (+0.79%)

Closing price 08/27/2026 03:59 PM Eastern

Extended Trading

$43.54 -0.16 (-0.37%)

As of 04:04 AM Eastern

Compare

QGEN vs. ILMN, MTD, MEDP, CRL, and RVTY

Should you buy Qiagen stock or one of its competitors? Qiagen's main competitors and comparable companies include Illumina (ILMN), Mettler-Toledo International (MTD), Medpace (MEDP), Charles River Laboratories International (CRL), and Revvity (RVTY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Qiagen compare to Illumina?

Illumina (NASDAQ:ILMN) and Qiagen (NYSE:QGEN) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Illumina has higher revenue and earnings than Qiagen. Qiagen is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Illumina	$4.34B	7.92	$850M	$5.36	42.48
Qiagen	$2.09B	4.31	$424.88M	$1.95	22.41

89.4% of Illumina shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 2.9% of Illumina shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Illumina presently has a consensus price target of $188.40, suggesting a potential downside of 17.26%. Qiagen has a consensus price target of $43.93, suggesting a potential upside of 0.51%. Given Qiagen's higher probable upside, analysts plainly believe Qiagen is more favorable than Illumina.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Illumina	2 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.47
Qiagen	0 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.43

Illumina has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

In the previous week, Illumina had 35 more articles in the media than Qiagen. MarketBeat recorded 53 mentions for Illumina and 18 mentions for Qiagen. Illumina's average media sentiment score of 1.10 beat Qiagen's score of 0.16 indicating that Illumina is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Illumina	38 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Qiagen has a net margin of 19.49% compared to Illumina's net margin of 18.36%. Illumina's return on equity of 29.84% beat Qiagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Illumina	18.36%	29.84%	12.17%
Qiagen	19.49%	14.47%	8.34%

Summary

Illumina beats Qiagen on 13 of the 16 factors compared between the two stocks.

How does Qiagen compare to Mettler-Toledo International?

Qiagen (NYSE:QGEN) and Mettler-Toledo International (NYSE:MTD) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

In the previous week, Mettler-Toledo International had 5 more articles in the media than Qiagen. MarketBeat recorded 23 mentions for Mettler-Toledo International and 18 mentions for Qiagen. Mettler-Toledo International's average media sentiment score of 1.51 beat Qiagen's score of 0.16 indicating that Mettler-Toledo International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mettler-Toledo International	22 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Qiagen has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, Mettler-Toledo International has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

Mettler-Toledo International has higher revenue and earnings than Qiagen. Qiagen is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	4.31	$424.88M	$1.95	22.41
Mettler-Toledo International	$4.03B	7.00	$869.19M	$44.43	31.67

70.0% of Qiagen shares are owned by institutional investors. Comparatively, 95.1% of Mettler-Toledo International shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 0.7% of Mettler-Toledo International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Mettler-Toledo International has a net margin of 21.91% compared to Qiagen's net margin of 19.49%. Qiagen's return on equity of 14.47% beat Mettler-Toledo International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.49%	14.47%	8.34%
Mettler-Toledo International	21.91%	-1,212.14%	25.11%

Qiagen currently has a consensus target price of $43.93, indicating a potential upside of 0.51%. Mettler-Toledo International has a consensus target price of $1,461.27, indicating a potential upside of 3.84%. Given Mettler-Toledo International's stronger consensus rating and higher possible upside, analysts plainly believe Mettler-Toledo International is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.43
Mettler-Toledo International	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46

Summary

Mettler-Toledo International beats Qiagen on 14 of the 17 factors compared between the two stocks.

How does Qiagen compare to Medpace?

Qiagen (NYSE:QGEN) and Medpace (NASDAQ:MEDP) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Qiagen has a net margin of 19.49% compared to Medpace's net margin of 17.67%. Medpace's return on equity of 110.15% beat Qiagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.49%	14.47%	8.34%
Medpace	17.67%	110.15%	24.84%

70.0% of Qiagen shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 20.5% of Medpace shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Qiagen has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market. Comparatively, Medpace has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

In the previous week, Medpace had 29 more articles in the media than Qiagen. MarketBeat recorded 47 mentions for Medpace and 18 mentions for Qiagen. Medpace's average media sentiment score of 0.99 beat Qiagen's score of 0.16 indicating that Medpace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medpace	32 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen currently has a consensus price target of $43.93, indicating a potential upside of 0.51%. Medpace has a consensus price target of $584.18, indicating a potential downside of 4.48%. Given Qiagen's stronger consensus rating and higher possible upside, research analysts plainly believe Qiagen is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.43
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23

Medpace has higher revenue and earnings than Qiagen. Qiagen is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	4.31	$424.88M	$1.95	22.41
Medpace	$2.53B	6.75	$451.12M	$17.06	35.85

Summary

Medpace beats Qiagen on 12 of the 17 factors compared between the two stocks.

How does Qiagen compare to Charles River Laboratories International?

Charles River Laboratories International (NYSE:CRL) and Qiagen (NYSE:QGEN) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

98.9% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Charles River Laboratories International has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

Qiagen has a net margin of 19.49% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Qiagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-5.96%	15.75%	6.51%
Qiagen	19.49%	14.47%	8.34%

Qiagen has lower revenue, but higher earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	3.53	-$144.34M	-$4.85	N/A
Qiagen	$2.09B	4.31	$424.88M	$1.95	22.41

Charles River Laboratories International currently has a consensus price target of $255.65, indicating a potential downside of 13.91%. Qiagen has a consensus price target of $43.93, indicating a potential upside of 0.51%. Given Qiagen's higher probable upside, analysts plainly believe Qiagen is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69
Qiagen	0 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.43

In the previous week, Charles River Laboratories International and Charles River Laboratories International both had 18 articles in the media. Charles River Laboratories International's average media sentiment score of 0.37 beat Qiagen's score of 0.16 indicating that Charles River Laboratories International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Qiagen	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Qiagen beats Charles River Laboratories International on 9 of the 16 factors compared between the two stocks.

How does Qiagen compare to Revvity?

Qiagen (NYSE:QGEN) and Revvity (NYSE:RVTY) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

Qiagen currently has a consensus price target of $43.93, suggesting a potential upside of 0.51%. Revvity has a consensus price target of $108.36, suggesting a potential downside of 16.19%. Given Qiagen's stronger consensus rating and higher probable upside, analysts clearly believe Qiagen is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.43
Revvity	0 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Qiagen has higher earnings, but lower revenue than Revvity. Qiagen is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	4.31	$424.88M	$1.95	22.41
Revvity	$2.91B	4.96	$241.20M	$2.10	61.57

In the previous week, Revvity had 14 more articles in the media than Qiagen. MarketBeat recorded 32 mentions for Revvity and 18 mentions for Qiagen. Revvity's average media sentiment score of 1.06 beat Qiagen's score of 0.16 indicating that Revvity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revvity	19 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Revvity has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

70.0% of Qiagen shares are held by institutional investors. Comparatively, 86.7% of Revvity shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Comparatively, 0.9% of Revvity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Qiagen has a net margin of 19.49% compared to Revvity's net margin of 8.16%. Qiagen's return on equity of 14.47% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.49%	14.47%	8.34%
Revvity	8.16%	8.34%	5.01%

Qiagen pays an annual dividend of $0.35 per share and has a dividend yield of 0.8%. Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.2%. Qiagen pays out 17.9% of its earnings in the form of a dividend. Revvity pays out 13.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Qiagen beats Revvity on 10 of the 19 factors compared between the two stocks.

Get Qiagen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QGEN vs. The Competition

Export

Metric	Qiagen	Life Sciences Tools & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$8.94B	$10.23B	$7.32B	$24.32B
Dividend Yield	0.81%	1.46%	2.53%	3.71%
P/E Ratio	22.39	63.28	271.30	30.24
Price / Sales	4.31	111.43	641.23	17.48
Price / Cash	12.73	26.95	79.17	33.18
Price / Book	2.68	37.67	13.02	7.68
Net Income	$424.88M	$56.67B	$3.46B	$1.07B
7 Day Performance	-1.24%	0.67%	1.00%	-0.30%
1 Month Performance	3.66%	9.55%	8.61%	1.63%
1 Year Performance	-9.89%	27.50%	26.57%	14.07%

Qiagen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QGEN Qiagen	2.8421 of 5 stars	$43.70 +0.8%	$43.93 +0.5%	-13.5%	$8.94B	$2.09B	22.39	5,654	Trending News Analyst Revision
ILMN Illumina	2.1845 of 5 stars	$223.22 +1.7%	$188.40 -15.6%	+128.7%	$33.13B	$4.34B	41.65	8,650	Positive News Insider Trade
MTD Mettler-Toledo International	3.8828 of 5 stars	$1,399.02 +0.3%	$1,461.27 +4.4%	+9.4%	$27.96B	$4.03B	31.49	18,100	Positive News
MEDP Medpace	2.9926 of 5 stars	$620.03 -0.1%	$584.18 -5.8%	+29.2%	$17.33B	$2.53B	36.34	6,200	Insider Trade
CRL Charles River Laboratories International	2.6271 of 5 stars	$298.76 +1.2%	$255.65 -14.4%	+82.6%	$14.09B	$4.02B	N/A	19,700	Trending News Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:QGEN) was last updated on 8/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Qiagen (QGEN) Competitors